PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF
申请人:Washington University
公开号:US20160279060A1
公开(公告)日:2016-09-29
The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.
本发明涵盖了前药组合物、包含一种或多种前药的纳米粒子,以及其使用方法。
Interferon beta: remodeling and glycoconjugation of interferon beta
申请人:Neose Technologies, Inc.
公开号:US20040115168A1
公开(公告)日:2004-06-17
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
本发明包括重塑肽分子的方法和组合物,包括向肽添加或删除一个或多个糖基团,和/或向肽添加修饰基团。
Glycoconjugation methods and proteins/peptides produced by the methods
申请人:Neose Technologies, Inc.
公开号:US20040142856A1
公开(公告)日:2004-07-22
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
本发明包括重塑肽分子的方法和组合物,包括向肽添加或删除一个或多个糖基团,和/或向肽添加修饰基团。
Interleukin-2:remodeling and glycoconjugation of interleukin-2
申请人:DeFrees Shawn
公开号:US20050031584A1
公开(公告)日:2005-02-10
The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.
Making the SF<sub>5</sub>
Group More Accessible: A Gas-Reagent-Free Approach to Aryl Tetrafluoro-λ<sup>6</sup>
-sulfanyl Chlorides
作者:Cody Ross Pitts、Dustin Bornemann、Phil Liebing、Nico Santschi、Antonio Togni
DOI:10.1002/anie.201812356
日期:2019.2.11
first approach to aryl‐SF4Cl compounds (key intermediates in state‐of‐the‐art aryl‐SF5 synthesis) that overcomes the reliance on hazardous fluorinating reagents and/or gas reagents (e.g. Cl2) by employing easy‐to‐handle trichloroisocyanuric acid, potassium fluoride, and catalytic amounts of acid. These simple, mild conditions allow direct access to aryl‐SF4Cl intermediates that either have not been or